Home > Insider Trading > Filing (0001104659-20-137408)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1760542	Hookipa Pharma Inc.	HOOK	Pharmaceutical Preparations (2834)	815395687

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1768208	Igor Matushansky	C/O Hookipa Pharma Inc. 350 Fifth Avenue, 72Nd Floor, Suite 7240 New York NY 10118	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-12-16	640	$0.10	56,774	No	4	M	Direct
Common Stock	Disposition	2020-12-16	380	$11.70	56,394	No	4	S	Direct
Common Stock	Acquisiton	2020-12-17	19,360	$0.10	75,754	No	4	M	Direct
Common Stock	Disposition	2020-12-17	11,501	$11.70	64,253	No	4	S	Direct
Common Stock	Acquisiton	2020-12-17	29,628	$0.10	93,881	No	4	M	Direct
Common Stock	Disposition	2020-12-17	16,478	$11.76	77,403	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-12-16	640	$0.00	640	$0.10
Common Stock	Stock Option (Right to Buy)	Disposition	2020-12-17	31,656	$0.00	31,656	$0.10
Common Stock	Stock Option (Right to Buy)	Disposition	2020-12-17	11,367	$0.00	11,367	$0.10
Common Stock	Stock Option (Right to Buy)	Disposition	2020-12-17	5,965	$0.00	5,965	$0.10

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
39,735	2026-12-31	No	4	M	Direct
8,079	2026-12-31	No	4	M	Direct
14,208	2026-12-31	No	4	M	Direct
7,669	2026-12-31	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were in connection with the satisfaction of tax obligations and the shares retained upon exercise remain subject to a lockup agreement which expires on March 8, 2021.
25% of this option vested and became exercisable on March 1, 2018, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 129,212 shares and the Reporting Person has exercised his option to purchase 121,133 shares.
25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 45,466 shares and the Reporting Person has exercised his option to purchase 31,258 shares.
25% of this option vested and became exercisable on January 1, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 13,634 shares and the Reporting Person has exercised his option to purchase 5,965 shares.